Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
Disease Category: Solid Tumors

Trial Information

Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients with Advanced Solid Tumors and in Chemotherapy-Naive Patients with Malignant Pleural Mesothelioma

You have been asked to participate in this research study because you have malignant pleural mesothelioma (MPM) and have not received any chemotherapy for this disease. The purpose of this research study is to evaluate the safety and effectiveness of CBP501, pemetrexed and cisplatin when compared to pemetrexed and cisplatin alone in the treatment of mesothelioma. Repeated blood samples will be taken before and after the first dose of CBP501 is given to study the levels of CBP501 that stay in the body over time. Your treatment on this study is expected to last for as long as your tumor is not growing and you are not having any unmanageable side effects. After your treatment on this study is over, your medical condition will continue to be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.